The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Banned: Key Facts on the Latest FDA Decision Bacteriostatic Water for Peptide Reconstitution Australia IM AEGYO FDA Compliance for Peptide Therapy and BPC 157 Holt Law